Aspen Pharmacare has seen some financial weakness lately, but that hasn’t stopped it from pledging to make its largest manufacturing investment ever. The South African drugmaker says it will invest nearly $235 million in a facility to manufacture sterile anesthetics.
The announcement was made Friday at a government sponsored economic conference in the country. Stavros Nicolaou, Aspen senior executive offered few details, saying only that the R3.4 billion facility would be built at its Port Elizabeth manufacturing site and that it offered a high tech manufacturing niche “that presents both domestic and export opportunities.”
The company has said that the sterile anesthetics drug facility, along with a high containment facility that it opened in May, will allow Aspen to add 500 jobs at the Port Elizabeth site.
“Aspen has become one of the global leaders in a number of niche, specialty therapeutic segments, such as anesthetic, high potency and injectable anti-coagulant products, which present highly specialized public and private health opportunities,” Nicolaou said.
The $80 million, 23,000 square-meter, high potency facility opened last spring produces specialized meds like alkeran, leukeran and purinethol for cancer, as well as Parkinson’s disease drug benztropine.
The company’s share price has fallen by nearly half since September when it reported weaker than expected financial results. At the time it also said (PDF) it would sell its nutrition business to Lactalis Group for €740 million. Analysts told BusinessDay that in addition to the weak numbers, the sale of the nutrition business for half what some expected has weighed on the company’s share price.
By Eric Palmer
Source: Fierce Pharma
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).